buscopan uses and mechanism in paediatrics
Reading File
Finding Sources
Finding Sources
Searching PubMed
hyoscine butylbromide children
Reading File
Finding Sources
Searching PubMed
hyoscine butylbromide abdominal pain pediatric
Reading Article
PMID: 40364041
Finding Sources
Searching the Web
buscopan hyoscine butylbromide paediatric uses mechanism dosing
Here is a thorough overview of Buscopan (hyoscine butylbromide) in paediatrics:
Buscopan (Hyoscine Butylbromide) in Paediatrics
What is it?
Buscopan is the brand name for hyoscine butylbromide (HBB), a quaternary ammonium anticholinergic/antispasmodic classified by the WHO as an indispensable drug. It is distinct from hyoscine hydrobromide (scopolamine), which crosses the blood-brain barrier; HBB does not enter the CNS, making it much safer in terms of central side effects. - Maudsley Prescribing Guidelines, 15th ed.
Mechanism of Action
HBB works through several complementary pathways:
- Muscarinic receptor antagonism (M3): Blocks the action of acetylcholine at muscarinic receptors in the smooth muscle of the GI, biliary, and urinary tracts, reducing involuntary smooth muscle contraction (spasm).
- Ganglionic blockade: Exhibits marked ganglionic blocking properties at the level of the parasympathetic ganglia in the gut wall (intramural ganglia), further reducing peristaltic drive.
- Curariform (neuromuscular) properties: Mild neuromuscular blocking action contributes to smooth muscle relaxation.
- Peripheral-only action: Because it is a quaternary ammonium compound, HBB is not absorbed from the gut lumen to any significant degree and does not cross the BBB. Central anticholinergic effects (sedation, confusion, hallucinations) are therefore rare.
The net result is spasmolysis without significant loss of basal tone - it relieves the spasm while preserving normal gut function. - Pediatric Oncall Drug Index
Clinical Uses in Paediatrics
Approved Indications
- Abdominal/gastrointestinal cramps and spasm - the primary indication (approved for children ≥6 years for tablets; syrup formulation available for younger children)
- Renal colic - ureteric smooth muscle spasm
- Biliary colic - biliary tract spasm
Off-Label / Evidence-Supported Uses
Based on the 2025 comprehensive review (Vázquez Frías et al., JCM 2025, PMID 40364041), studies cover children from as young as 2 days of age:
| Use | Evidence |
|---|---|
| Procedural analgesia / general anaesthesia | Multiple studies |
| Diagnostic procedures (GI endoscopy, imaging) | Used to abolish duodenal motility for better visualisation |
| Infantile colic | Off-label, some case series |
| Labour facilitation (via maternal use - fetal safety data available) | 17 RCTs |
Dosing in Paediatrics
| Age Group | Route | Dose |
|---|---|---|
| Children 6-12 years | Oral (tablet 10 mg) | 10 mg (1 tablet) 3× daily |
| Adults & children ≥12 years | Oral | 10-20 mg 3-4× daily |
| Infants & young children (severe cases) | IV/IM/SC (slow) | 0.3-0.6 mg/kg, several times daily |
| Infants & children | Injectable (max daily) | 1.2 mg/kg/day |
| Adults injectable | IV/IM | 20 mg, repeat after 30 min; max 100 mg/day |
Syrup formulation: Buscopan 0.1% syrup (5 mg/5 mL) is available for infants and children under 6 years.
IV injection should be administered slowly - rapid IV can cause a marked drop in blood pressure.
Contraindications in Paediatrics
- Myasthenia gravis
- Mechanical stenosis / obstructive or paralytic ileus
- Megacolon
- Narrow-angle glaucoma
- Tachycardia
- Fever (additional caution - anticholinergics impair sweating)
- Porphyria
- Known hypersensitivity to HBB
Adverse Effects
Due to its anticholinergic action (peripheral):
- Dry mouth
- Constipation
- Tachycardia (most clinically relevant - monitor in children)
- Urinary retention
- Visual accommodation disturbances
- Less common: rash, dizziness, diarrhoea
Central effects (sedation, confusion) are not expected due to poor CNS penetration.
Drug Interactions
| Drug Class | Interaction |
|---|---|
| Tricyclic antidepressants, antihistamines, antipsychotics, quinidine, amantadine, disopyramide | Additive anticholinergic effects |
| Metoclopramide | Opposing GI effects - both drugs' efficacy reduced |
| Beta-agonists | Enhanced tachycardia |
Safety Profile in Children
The 2025 comprehensive review (PMID 40364041) covering thousands of patients in RCTs, case series, and non-randomised trials found no safety concerns in infants and children, including those younger than the approved age of 6 years. The authors note that additional dedicated paediatric RCTs on efficacy are still needed.
Key Takeaway
Buscopan is a safe, effective peripheral antispasmodic for paediatric GI spasm. Its lack of CNS penetration makes it preferable to atropine or hyoscine hydrobromide in children when only peripheral spasmolysis is needed. The oral tablet is licensed from age 6, and syrup/injectable forms extend use to younger children and infants under clinical supervision.
This is a shared conversation. Sign in to Orris to start your own chat.